Samaritan CEO Janet Greeson Honored as One of "100 of the Most Inspiring People in Life Sciences" by PharmaVOICE Magazine.

LAS VEGAS -- Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, announced its CEO, Dr. Janet Greeson has been selected by PharmaVOICE magazine to be one of the Fourth Annual PharmaVOICE 100, "100 of The Most Inspiring People in Life Sciences."

http://www.pharmavoice.com/archives/article.esiml?id=1377

PharmaVOICE 100: "Dr. Janet Greeson is not afraid to dream big, never letting fear paralyze her, and is constantly energized to make a difference. Her frank and open confidence in her capabilities is measured equally by her confidence in others. A passion for life, a positive attitude and a relentless desire to make a difference drives her."

Dr. Greeson, as CEO since 2001, has transformed Samaritan Pharmaceuticals from a one-drug company into a company with a pipeline full of potential blockbusters and proactively strategized to create a self-sustaining, revenue stream, by marketing and selling specialty drugs, in Greece and Eastern Europe.

About the PharmaVOICE 100

The 2008 PharmaVOICE 100 were nominated by PharmaVOICE's diverse readership who identified the individuals they consider to be the most inspiring and who provide the greatest influence and positive impact on corporate leadership within the life-sciences industry. These individuals will be featured in the fourth annual July/August PharmaVOICE 100 issue.

Readers were asked to select individuals who view industry trends as challenges, not burdens, as opportunities not obstacles; who embody panache and conviction; and who plan for the future rather than respond to change.

The 2008 PharmaVOICE 100 were selected based on a number of criteria, including submissions from thousands of readers who took the time to provide personal, compelling, and comprehensive essays as to how and why an individual inspired or motivated them or affected positive change in their organization or team.

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "Although I am totally flattered, this honor belongs to all of us on the Samaritan team. In reality, none of us can accomplish much on our own. Together, we have embraced the current environment as a challenge, turned obstacles into opportunities and we embody the panache to succeed in bringing life-saving drugs to suffering patients."

"The PharmaVOICE 100 are individuals who inspire their colleagues and peers; they motivate those around them to succeed and reach beyond their expectations; they think outside of the box to create new business processes and models; and they are pioneers, often forging new paths to success," said Taren Grom, editor-in-chief and cofounder of PharmaVOICE. "We are extremely pleased and honored to recognize these 100 individuals who come from all of the different sectors of the industry. They are personally influencing those around them through their positive actions. They have the unique ability to translate industry issues into opportunities, and they take the time to mentor the next generation of leaders in the life-sciences arena."

About PharmaVOICE

PharmaVOICE, Titusville, N.J., is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry.

About Samaritan Pharmaceuticals

Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company committed to bringing innovative life-saving drugs to patients suffering with Alzheimer's disease; cancer; cardiovascular disease, HIV, and Hepatitis C; as well as, commercializing branded revenue-generating products in Greece and Eastern European countries. Our commercialization business model focuses on achieving growth and maximizing value for the benefit of our investors.

Marketed Products

Samaritan has distribution rights to sell specialty pharmaceutical products such as, Amphocil from Three Rivers Pharmaceuticals, Elaprase and Replagal from Shire Pharmaceuticals, Infasurf from Ony, Inc, Erwinase, Kidrolase, and the Rapydan pain patch from EUSA, Mepivamol, Methadone, Morphine Sulphate, Naloxone, Naltrexone, Oramorph and Pethidine from Molteni Farmaceutici and Abioklad from Abiogen Pharma.

http://www.samaritanpharma.com Please register so we can notify you of upcoming conference calls, news, and events and check out videos.

Disclaimer

The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 14, 2008. The company undertakes no duty to update forward-looking statements.